Every article, presentation, spotlight, and news item we've tagged to Supplements and Compounds.
Showing 49–72 of 175
Fractyl Health has received regulatory approval to initiate Phase 1/2 trials of RJVA-001, a single-administration gene therapy designed to enable patients' own cells to produce GLP-1 indefinitely. This represents a shift toward durable metabolic interventions that require one-time dosing rather than ongoing pharmaceutical management.
A pilot study demonstrates that Lactiplantibacillus plantarum OL3246 improves quality of life in aging adults through measurable reductions in inflammatory markers and shifts in gut microbiota composition. This probiotic strain shows potential as a targeted intervention for mitigating age-related inflammatory decline.
IMCIVREE (setmelanotide) received FDA approval as the first therapy for acquired hypothalamic obesity, a rare condition where brain injury disrupts hunger and energy regulation. The Phase 3 TRANSCEND trial demonstrated an 18.4% BMI reduction versus placebo at 52 weeks, addressing a previously untreated disorder that causes relentless weight gain despite behavioral intervention.
CSPC Pharmaceutical's SYH2082, a once-monthly GLP-1/GIP receptor agonist, has received FDA approval to begin US clinical trials. The extended dosing interval addresses a critical barrier to treatment adherence that weekly alternatives have not solved, with potential implications for sustainable weight management and metabolic disease prevention.
Aging impairs intestinal mitochondrial energy production, reducing HDL3 synthesis and disrupting the gut-liver axis, allowing inflammatory lipopolysaccharide to damage the liver. NMN restores NAD+ availability, rebuilds HDL3 production, and reverses this age-related hepatic injury in experimental models.
Losartan, an angiotensin II receptor blocker, partially reversed aging-related metabolomic signatures in both aged mice and pre-frail older men, with effects dependent on functional angiotensin II receptors and correlating with improved survival in treated mice. The drug produced dose-dependent metabolic rejuvenation in humans and normalized age-related shifts in circulating metabolites, particularly lipids and amino acids.
RNASEK, an enzyme that degrades circular RNA accumulation in cells, extends lifespan in model organisms by removing a form of molecular waste that accelerates aging. This identifies a specific degradation pathway central to cellular longevity.
Kailera Therapeutics, backed by $1.6 billion in funding, is pursuing an IPO to advance its GLP-1-based obesity drug pipeline, with ribupatide showing 18-23% weight loss in trials. The company's capital requirements reflect how quickly the competitive landscape has shifted—efficacy alone no longer differentiates; payers now demand real-world outcomes data and cost justification.
LinkGevity is developing a small-molecule therapeutic targeting necrosis—uncontrolled cell death—as an upstream driver of multiple age-related diseases. By intervening at this central physiological node, the approach aims to address degenerative change across chronic conditions simultaneously rather than treating diseases individually.
SLC25A51, a mitochondrial NAD transporter in fat cells, declines with age and directly regulates adipose tissue energy metabolism and systemic insulin sensitivity. Loss of this transporter accelerates metabolic disease phenotypes; its restoration protects against obesity and insulin resistance in aging.
A 12-week study of 245 adults with obesity found that Omada's GLP-1 Care Track program—combining pharmacotherapy with structured exercise, coaching, and digital tracking—achieved 1.8-fold greater weight loss and nearly threefold greater muscle preservation compared to GLP-1 monotherapy alone. This differential body composition outcome has direct implications for maintaining metabolic capacity and physical function during intentional weight reduction.
Insilico Medicine and Tenacia Biotechnology are expanding their AI-driven collaboration to design small-molecule therapies for central nervous system disorders, with a focus on blood-brain barrier penetration. This partnership demonstrates how generative AI can accelerate drug discovery for neurological conditions, including a candidate targeting NLRP3 inflammation that has cleared FDA review for Parkinson's disease trials.
Senescent cell immunogenicity varies substantially by cell type and the trigger that induced senescence. RAS-induced senescent myoblasts activated immune responses, while senescent fibroblasts, endothelial cells, and lung progenitors showed limited or no immunogenicity despite expressing senescence markers.
D-pinitol, a naturally occurring inositol derivative, extends lifespan in C. elegans by coordinating three distinct cellular mechanisms: antioxidant defense, protein stability (proteostasis), and autophagy. This multi-pathway activation suggests a compound that addresses fundamental aging processes rather than targeting a single intervention point.
Temozolomide-induced senescent glioblastoma cells exhibit dynamic morphological states with distinct survival mechanisms and drug sensitivities. This heterogeneity and plasticity have direct implications for how chemotherapy resistance develops and why combination senotherapeutic strategies may be necessary to prevent tumor recurrence.
Designs for Health introduced NeuroCalm Peptide, combining a milk-derived peptide (Lactium) with a heat-treated Lactobacillus strain to modulate the gut-brain axis. Clinical evidence suggests the formulation may reduce perceived stress and salivary cortisol while supporting sleep quality and emotional resilience through microbiome and nervous system pathways.
TrenibotE, an investigational neurotoxin, demonstrated consistent safety across repeat treatments with rapid onset at eight hours and duration of two to three weeks, with no neutralizing antibody development. Concurrent survey data indicate that over half of GLP-1–treated patients express concerns about facial appearance, with cost and fear of unnatural results as primary barriers to aesthetic intervention.
Pfizer's PF-3944 demonstrated 11-12 percentage points greater weight loss than placebo in Phase 2b trials with monthly dosing, maintaining efficacy without plateau at 28 weeks. The drug's clinical promise is offset by higher discontinuation rates due to gastrointestinal side effects and direct comparison disadvantage relative to competitor therapies.
AstraZeneca's $18.5 billion licensing deal with CSPC Pharmaceutical Group targets next-generation obesity therapeutics, particularly SYH2082, designed for improved patient adherence and reduced cardiometabolic complications. Once-monthly dosing and AI-enabled peptide platforms position these agents as tools for sustained weight management and prevention of obesity-related disease burden.
A partnership between Science Corporation and Neurosoft Bioelectronics reduces brain-computer interface development costs from $75–100 million to under $5 million, accelerating clinical adoption of therapies for neurological conditions including epilepsy and tinnitus. For longevity practitioners, this infrastructure advancement enables faster restoration of neurological function and cognitive independence—essential dimensions of healthspan that outlive lifespan alone.
Aspen Neuroscience's Phase 1/2a trial of sasineprocel (ANPD001), a cell-based therapy for Parkinson's disease, demonstrated safety and functional improvements at 12 months in eight patients, with gains in motor function, quality of life, and reduced medication burden. These results support advancement to Phase 3 evaluation of a regenerative approach to dopaminergic neurodegeneration.
Jupiter Neurosciences is positioning its Nugevia supplement line to support individuals using GLP-1 weight-loss medications, targeting the physiological demands these drugs place on mitochondrial function, lean tissue preservation, and metabolic signaling. This represents a market expansion that acknowledges the need for targeted support during rapid metabolic change induced by pharmacological intervention.
Aspen Neuroscience received WHO and AMA approval for the official name Sasineprocel for its autologous dopaminergic cell therapy derived from patient skin cells. The therapy aims to restore dopamine-producing neurons in Parkinson's disease without immunosuppression, currently in Phase 1/2a trials.
Alveus Therapeutics raised $197 million in Series A funding to advance next-generation obesity treatments, including ALV-100, which combines two metabolic signaling pathways to achieve durable weight loss, and ALV-200, an amylin receptor agonist representing a potential frontier beyond current GLP-1 approaches. This capital deployment reflects the biomedical sector's recognition of obesity as a chronic metabolic disease requiring mechanistically distinct therapeutic strategies.
